Endocrine Therapy

Black women with advanced-stage hormone receptor-positive breast cancer experienced poor response to treatment with neoadjuvant endocrine therapy compared with white women with similar disease presentation, according to study results.

Medicaid-insured women diagnosed with primary hormone receptor-positive breast cancer had lower odds of short- and long-term adherence to adjuvant endocrine therapy if they had a longer time to initiation of the therapy.

CHICAGO — The addition of chemotherapy to endocrine therapy did not extend OS after surgery among older patients with ER-positive, HER2-negative breast cancer with a high tumor genomic grade index.

Erminia Massarelli, MD, PhD, MS, co-director of the lung cancer and thoracic oncology program, and associate professor in the department of medical oncology and therapeutics research at City of Hope Cancer Center in Duarte, California, spoke with Healio about treatments in the pipeline for EGFR-mutated lung cancer.

In this video, Payal Shah, MD, assistant professor of medicine at the hospital of the University of Pennsylvania, spoke with Healio about the ongoing HOPE trial.

In this video, Angela DeMichele, MD, MSCE, co-leader of the Breast Cancer Research Program and director of the Breast Cancer Clinical Trials Unit at Penn Medicine, discusses results from the PALLAS trial assessing palbociclib in early breast cancer.

The addition of palbociclib to endocrine therapy prolonged survival for Black and Hispanic women with hormone receptor-positive, HER2-negative metastatic breast cancer, according to results presented at San Antonio Breast Cancer Symposium.

Megan Kruse, MD, a breast medical oncologist at Cleveland Clinic, spoke with Healio about results from her research on real-world sequential and non-sequential use of CDK4/6 inhibitors in a subset of breast cancer patients.

A longer duration of extended hormone therapy provided no benefit for postmenopausal women with hormone receptor-positive breast cancer who had received 5 years of adjuvant endocrine therapy, according to randomized phase 3 study results.

Palbociclib plus endocrine therapy was not associated with lowered quality of life among Black, indigenous and people of color with HR-positive, HER2-negative advanced breast cancer, according to research presented at ASCO 2021.